Structure Therapeutics (NASDAQ:GPCR) Hits New 1-Year Low – Here’s Why

Structure Therapeutics Inc. (NASDAQ:GPCR) shares reached a new 52-week low during trading on Wednesday . The stock traded as low as $13.22 and last traded at $13.91, with a volume of 123479 shares. The stock had previously closed at $14.15.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. JMP Securities reissued a “market outperform” rating and set a $91.00 target price on shares of Structure Therapeutics in a report on Wednesday, December 18th. William Blair initiated coverage on Structure Therapeutics in a report on Friday, February 28th. They set an “outperform” rating on the stock. Stifel Nicolaus assumed coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They issued a “buy” rating and a $50.00 target price for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $80.00 price target on shares of Structure Therapeutics in a research report on Thursday, December 19th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, Structure Therapeutics currently has a consensus rating of “Buy” and an average target price of $81.29.

Structure Therapeutics Stock Down 2.0 %

The firm has a market capitalization of $795.52 million, a P/E ratio of -18.75 and a beta of -1.35. The firm’s 50-day simple moving average is $22.12 and its 200-day simple moving average is $29.86.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. As a group, analysts expect that Structure Therapeutics Inc. will post -0.82 EPS for the current fiscal year.

Hedge Funds Weigh In On Structure Therapeutics

A number of large investors have recently modified their holdings of GPCR. Deep Track Capital LP grew its position in Structure Therapeutics by 129.4% during the fourth quarter. Deep Track Capital LP now owns 2,800,000 shares of the company’s stock valued at $75,936,000 after acquiring an additional 1,579,492 shares during the last quarter. Vestal Point Capital LP grew its holdings in shares of Structure Therapeutics by 50.0% during the 4th quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock valued at $46,782,000 after purchasing an additional 575,000 shares during the last quarter. Boxer Capital Management LLC bought a new position in shares of Structure Therapeutics during the 4th quarter valued at $13,560,000. Marshall Wace LLP raised its position in Structure Therapeutics by 339.6% in the 4th quarter. Marshall Wace LLP now owns 583,207 shares of the company’s stock worth $15,817,000 after purchasing an additional 450,531 shares during the period. Finally, Foresite Capital Management VI LLC bought a new stake in Structure Therapeutics in the fourth quarter worth $11,390,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.